Research programme: fusion proteins - Symphogen

Drug Profile

Research programme: fusion proteins - Symphogen

Alternative Names: RB 200; RBLX-200; RBLX-242; Sym 011

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Receptor BioLogix
  • Developer Symphogen
  • Class Immunoglobulin Fc fragments; Recombinant fusion proteins
  • Mechanism of Action Epidermal growth factor receptor modulators; ERBB-3 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Denmark (Parenteral)
  • 08 Mar 2011 Preclinical trials in Cancer in Denmark (Parenteral)
  • 19 May 2010 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top